and make it possible [1%:<18 years of age) have not been established. 1 Geriatric Use Of the 1472 subjects with atopic dermatitis exposed to dupilumab in a dose-ranging study and placebo-controlled trials, 67 subjects were 65 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects. 1 Common Adverse Effects Most common adverse reactions (incidence 1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. 1 Drug Interactions Specific Drugs It is essential that the manufacturer's labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights: Live Vaccines : Avoid use of live vaccines with dupilumab. 1 Actions Mechanism of Action Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and IgE. 1 Advice to Patients Advise the patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use) before the patient starts using dupilumab and each time the prescription is renewed as there may be new information they need to know. 1 Administration Instructions Provide proper training to patients and/or caregivers on proper subcutaneous injection technique, including aseptic technique, and the preparation and administration of dupilumab prior to use. Advise patients to follow sharps disposal recommendations. 1 Hypersensitivity Advise patients to discontinue dupilumab and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions. 1 Conjunctivitis and Keratitis Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop. 1 Comorbid Asthma Advise patients with comorbid asthma not to adjust or stop their asthma treatment without talking to their physicians. 1 Additional Information AHFS First Release . For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity. Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Dupilumab Routes Dosage Forms Strengths Brand Names Manufacturer Parenteral Injection, Solution 300 mg /2 mL Dupixent Sanofi-Aventis U.S. LLC AHFS Drug Information. Copyright 2017, Selected Revisions April 7, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Sanofi-Aventis U.S. LLC. Dupixent (Dupilumab) SUBCUTANEOUS prescribing information. March 2017. Next Interactions Print this page Add to My Med List More about Dupixent (dupilumab) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 29 Reviews Add your own review/rating Drug class: interleukin inhibitors Consumer resources Dupixent Dupixent (Advanced Reading) Professional resources Dupixent (FDA) Dupilumab (AHFS Monograph) Related treatment guides Atopic Dermatitis Eczema> ] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Sanofi-Aventis U.S. LLC Drug Class Interleukin inhibitors Related Drugs Atopic Dermatitis prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , methylprednisolone , clobetasol topical , betamethasone topical , doxepin topical , mometasone topical , Kenalog , fluocinonide topical , More... Eczema prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , clobetasol topical , doxepin topical , mometasone topical , Kenalog , fluocinonide topical , desonide topical , More... Dupixent Rating 29 User Reviews 8.1 /10 29 User Reviews 8.1 Rate it! in search of
images Dupixent that offer
EmoticonEmoticon